Perpetual Ltd Has $57.20 Million Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Perpetual Ltd raised its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 54.0% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 475,018 shares of the specialty pharmaceutical company's stock after purchasing an additional 166,543 shares during the period. Perpetual Ltd owned about 0.75% of Jazz Pharmaceuticals worth $57,202,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Rise Advisors LLC lifted its holdings in Jazz Pharmaceuticals by 2,255.6% during the 1st quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company's stock worth $26,000 after buying an additional 203 shares during the last quarter. Cape Investment Advisory Inc. lifted its stake in Jazz Pharmaceuticals by 14,600.0% during the fourth quarter. Cape Investment Advisory Inc. now owns 294 shares of the specialty pharmaceutical company's stock worth $36,000 after purchasing an additional 292 shares during the last quarter. Covestor Ltd boosted its holdings in Jazz Pharmaceuticals by 676.5% in the third quarter. Covestor Ltd now owns 396 shares of the specialty pharmaceutical company's stock worth $51,000 after purchasing an additional 345 shares during the period. Headinvest LLC bought a new stake in Jazz Pharmaceuticals during the third quarter valued at $56,000. Finally, Assetmark Inc. increased its stake in Jazz Pharmaceuticals by 37.1% during the fourth quarter. Assetmark Inc. now owns 440 shares of the specialty pharmaceutical company's stock valued at $54,000 after purchasing an additional 119 shares during the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, EVP Neena M. Patil sold 5,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $109.65, for a total transaction of $548,250.00. Following the transaction, the executive vice president now owns 36,629 shares of the company's stock, valued at approximately $4,016,369.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 4.40% of the company's stock.

Jazz Pharmaceuticals Trading Down 4.7 %

NASDAQ:JAZZ traded down $5.32 during trading hours on Thursday, hitting $107.36. 1,561,847 shares of the stock were exchanged, compared to its average volume of 688,094. The company has a market capitalization of $6.77 billion, a P/E ratio of 22.14, a price-to-earnings-growth ratio of 1.73 and a beta of 0.62. The company has a quick ratio of 1.90, a current ratio of 2.27 and a debt-to-equity ratio of 1.38. The company's 50 day moving average is $109.13 and its two-hundred day moving average is $117.32. Jazz Pharmaceuticals plc has a twelve month low of $103.01 and a twelve month high of $146.70.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its earnings results on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.53 by ($1.55). The business had revenue of $901.98 million for the quarter, compared to analyst estimates of $938.99 million. Jazz Pharmaceuticals had a net margin of 8.61% and a return on equity of 27.86%. On average, sell-side analysts anticipate that Jazz Pharmaceuticals plc will post 15.35 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

JAZZ has been the topic of a number of recent research reports. Truist Financial reiterated a "buy" rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 20th. Cantor Fitzgerald reiterated an "overweight" rating and set a $180.00 price target on shares of Jazz Pharmaceuticals in a report on Wednesday, April 10th. Barclays cut their price objective on shares of Jazz Pharmaceuticals from $230.00 to $200.00 and set an "overweight" rating on the stock in a research report on Friday, May 3rd. HC Wainwright reissued a "buy" rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Friday, May 3rd. Finally, Stifel Nicolaus increased their target price on Jazz Pharmaceuticals from $225.00 to $230.00 and gave the company a "buy" rating in a research note on Friday, March 15th. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $190.00.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.